[go: up one dir, main page]

SG11202103691SA - Target for anti-cancer therapy - Google Patents

Target for anti-cancer therapy

Info

Publication number
SG11202103691SA
SG11202103691SA SG11202103691SA SG11202103691SA SG11202103691SA SG 11202103691S A SG11202103691S A SG 11202103691SA SG 11202103691S A SG11202103691S A SG 11202103691SA SG 11202103691S A SG11202103691S A SG 11202103691SA SG 11202103691S A SG11202103691S A SG 11202103691SA
Authority
SG
Singapore
Prior art keywords
target
cancer therapy
cancer
therapy
Prior art date
Application number
SG11202103691SA
Inventor
Grahame James Mckenzie
Samuel Peter Barker
Original Assignee
Phoremost Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoremost Ltd filed Critical Phoremost Ltd
Publication of SG11202103691SA publication Critical patent/SG11202103691SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202103691SA 2018-10-16 2019-10-16 Target for anti-cancer therapy SG11202103691SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1816825.2A GB201816825D0 (en) 2018-10-16 2018-10-16 Target for anti-cancer therapy
PCT/GB2019/052954 WO2020079433A1 (en) 2018-10-16 2019-10-16 Target for anti-cancer therapy

Publications (1)

Publication Number Publication Date
SG11202103691SA true SG11202103691SA (en) 2021-05-28

Family

ID=64394886

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103691SA SG11202103691SA (en) 2018-10-16 2019-10-16 Target for anti-cancer therapy

Country Status (7)

Country Link
US (1) US20210393667A1 (en)
EP (1) EP3866796A1 (en)
JP (1) JP2022505047A (en)
CN (1) CN113226311A (en)
GB (1) GB201816825D0 (en)
SG (1) SG11202103691SA (en)
WO (1) WO2020079433A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034518A (en) 1989-05-23 1991-07-23 Southern Research Institute 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides
WO2001036003A2 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
CN104144701A (en) * 2012-01-09 2014-11-12 蒂尔坦制药有限公司 Combination therapy for the treatment of cancer
CN106459991B (en) * 2014-04-07 2021-03-05 洛孔法尔马有限公司 Novel agents and uses thereof
WO2016130581A2 (en) * 2015-02-09 2016-08-18 The Regents Of The University Of California Combination cancer therapy
EP4378957A3 (en) * 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
CN108601789A (en) * 2015-11-20 2018-09-28 生华生物科技股份有限公司 Tetracyclic quinolone analog combination therapies for treating cancer
US20210275630A1 (en) 2016-04-18 2021-09-09 Phoremost Limited Inactivation of dna repair as an anticancer therapy

Also Published As

Publication number Publication date
EP3866796A1 (en) 2021-08-25
GB201816825D0 (en) 2018-11-28
JP2022505047A (en) 2022-01-14
CN113226311A (en) 2021-08-06
WO2020079433A1 (en) 2020-04-23
US20210393667A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
IL254705B (en) Combination therapy for cancer
GB201804255D0 (en) Macrophage-based therapy
IL270905A (en) Anti-cancer combination therapy
ZA202005847B (en) Cancer therapy
SG11202103253YA (en) Therapeutic compounds
GB201716942D0 (en) Therapeutic compounds
GB201707212D0 (en) Gene therapy for ciliopathies
GB201819853D0 (en) Therapy
IL282093A (en) Combination therapy for cancer
GB201808150D0 (en) Therapeutic compounds
GB201704909D0 (en) Cancer therapy
SG11202103691SA (en) Target for anti-cancer therapy
GB201819721D0 (en) Target for anti-cancer therapy
GB201817385D0 (en) Therapy
GB201904765D0 (en) Target for anti-cancer therapy
IL259097A (en) Combination therapy for cancer
GB201717034D0 (en) Targets for anti-cancer therapy
GB201805557D0 (en) Therapy for ophthalmogical condtions
GB201815012D0 (en) Target
GB201820895D0 (en) Therapy
IL268046B1 (en) Peptides for therapy
GB201814038D0 (en) Ilven therapy
GB201906026D0 (en) Target
GB201806463D0 (en) Cancer therapy
GB201809828D0 (en) Combined hormal therapy